CVS Health Corporation (CVS) Receives Hold Rating from Deutsche Bank AG
CVS Health Corporation (NYSE:CVS)‘s stock had its “hold” rating restated by research analysts at Deutsche Bank AG in a research report issued on Tuesday. They presently have a $99.00 price objective on the pharmacy operator’s stock, down from their previous price objective of $108.00. Deutsche Bank AG’s target price would indicate a potential upside of 14.24% from the company’s current price.
A number of other equities analysts also recently weighed in on the company. Morgan Stanley downgraded CVS Health Corporation from an “overweight” rating to an “equal weight” rating and dropped their target price for the company from $111.00 to $104.00 in a report on Monday, June 20th. Credit Suisse Group AG reiterated an “outperform” rating and issued a $110.00 target price (down previously from $115.00) on shares of CVS Health Corporation in a report on Tuesday, October 4th. Robert W. Baird dropped their target price on CVS Health Corporation from $114.00 to $104.00 and set an “outperform” rating on the stock in a report on Monday, October 3rd. Leerink Swann reiterated an “outperform” rating and issued a $105.00 target price (down previously from $110.00) on shares of CVS Health Corporation in a report on Sunday, October 2nd. Finally, Jefferies Group restated a “buy” rating on shares of CVS Health Corporation in a report on Monday, July 4th. Five investment analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $112.02.
CVS Health Corporation (NYSE:CVS) traded up 0.594% on Tuesday, hitting $87.175. 2,559,628 shares of the stock were exchanged. The company has a market cap of $92.95 billion, a P/E ratio of 20.054 and a beta of 0.83. The company’s 50 day moving average price is $89.92 and its 200-day moving average price is $96.23. CVS Health Corporation has a one year low of $85.41 and a one year high of $106.67.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/18/cvs-health-corporation-cvs-receives-hold-rating-from-deutsche-bank-ag.html
CVS Health Corporation (NYSE:CVS) last issued its earnings results on Tuesday, August 2nd. The pharmacy operator reported $1.32 earnings per share for the quarter, beating analysts’ consensus estimates of $1.30 by $0.02. The company had revenue of $43.70 billion for the quarter, compared to the consensus estimate of $44.28 billion. CVS Health Corporation had a return on equity of 15.86% and a net margin of 2.88%. The firm’s quarterly revenue was up 17.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.19 EPS. Equities research analysts predict that CVS Health Corporation will post $5.86 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, November 3rd. Stockholders of record on Monday, October 24th will be paid a $0.425 dividend. The ex-dividend date of this dividend is Thursday, October 20th. This represents a $1.70 dividend on an annualized basis and a dividend yield of 1.96%. CVS Health Corporation’s dividend payout ratio (DPR) is presently 39.08%.
Hedge funds have recently made changes to their positions in the stock. Acrospire Investment Management LLC raised its stake in shares of CVS Health Corporation by 542.2% in the second quarter. Acrospire Investment Management LLC now owns 1,066 shares of the pharmacy operator’s stock worth $102,000 after buying an additional 900 shares during the period. MU Investments Co. Ltd. raised its stake in shares of CVS Health Corporation by 62.0% in the second quarter. MU Investments Co. Ltd. now owns 1,150 shares of the pharmacy operator’s stock worth $109,000 after buying an additional 440 shares during the period. Pinkerton Retirement Specialists LLC raised its stake in shares of CVS Health Corporation by 3,475.0% in the second quarter. Pinkerton Retirement Specialists LLC now owns 1,144 shares of the pharmacy operator’s stock worth $110,000 after buying an additional 1,112 shares during the period. D Orazio & Associates Inc. raised its stake in shares of CVS Health Corporation by 9.4% in the second quarter. D Orazio & Associates Inc. now owns 1,160 shares of the pharmacy operator’s stock worth $111,000 after buying an additional 100 shares during the period. Finally, Cantab Capital Partners LLP raised its stake in shares of CVS Health Corporation by 355.4% in the second quarter. Cantab Capital Partners LLP now owns 1,184 shares of the pharmacy operator’s stock worth $113,000 after buying an additional 924 shares during the last quarter. Institutional investors own 80.89% of the company’s stock.
About CVS Health Corporation
CVS Health Corporation, together with its subsidiaries (CVS Health), is a pharmacy company. The Company operates through three business segments: Pharmacy Services, Retail/LTC and Corporate. The Company offers a range of products and services, such as advising patients on their medications at its CVS Pharmacy locations, introducing programs to help control costs for its clients at CVS Caremark, how care is delivered to its patients with conditions through CVS Specialty, pharmacy care for the senior community through Omnicare.
Receive News & Ratings for CVS Health Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health Corporation and related companies with MarketBeat.com's FREE daily email newsletter.